Fig. 4

Effect of AAV-CF6 shRNA on pulmonary vascular remodeling. a Hematoxylin and eosin and IHC staining of (b) alpha-actin with an α-SMA antibody, (c) of macrophages with a CD68 antibody, and (d) of vascular proliferation of lung tissues with a PCNA antibody in the (a) sham, (b) -2w-MCT, (c) -2w-shRNA, (d) 2w-MCT and (e) 2w-shRNA groups, respectively. e Ratios of vascular medial thickness (i.e., smooth muscle thickness) to the outer diameter (total vessel wall thickness) of the small pulmonary arteries in the PAH and normal rats. f Numbers of CD68-positive macrophage cells per 20 high-power fields (HPFs). g Relative changes in the number of PCNA-positive cells in pulmonary arterial walls, which were significantly different from the number in the MCT-control group. **p < 0.01, *p < 0.05 compared with sham; †p < 0.05 compared with -2w-MCT; #p < 0.05 compared with -2w-shRNA; and @ p < 0.05 compared with 2w-MCT